Research Report Confirms Opportunity for Anavex Anti-Cancer and Neuropathic Pain Compounds

Sigma-1 Receptor Modulation Preventing Neuropathic Pain Induced by Paclitaxel New York, NY — February 26, 2014 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) today announced that a research article in the current issue of peer-reviewed scientific journal Molecular Pain reveals a new opportunity for the Company’s anti-cancer and neuropathic pain compounds. …

Sigma-1 Receptor Implicated in Cell Survival of Rare Neurodegenerative Diseases – Expanding the Opportunity for Application of ANAVEX PLUS in Rare Diseases

New York, NY — January 23, 2014 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) today announced that a publication in the current issue of scientific journal Neuropathology potentially extends the opportunity for ANAVEX PLUS to additional neurodegenerative diseases beyond Alzheimer’s. The report demonstrates for the first time, evidenced by human brain…

Anavex Agreement with the Roskamp Institute to Advance the Clinical Development of ANAVEX PLUS

New York, NY — January 13, 2014 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) today announced that they have established an agreement with The Roskamp Institute for the clinical development of ANAVEX PLUS, a new combination drug of ANAVEX 2-73 and donepezil (Aricept®) for the treatment of Alzheimer’s disease.  This study…

Anavex CEO Invited to Present at Upcoming Investment Conferences

New York, NY — January 7, 2014 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) today announced that its President and Chief Executive Officer Christopher U. Missling, PhD, will participate in the 7th Annual OneMedForum: Investing in Healthcare 2014 (“OneMedForum”) and the Noble Financial Capital Markets (“Noble”) Tenth Annual Equity Conference. OneMedForum…

Anavex Appoints Clinical Design Expert to Scientific Advisory Board

New York, NY — December 10, 2013 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) today announced the appointment of John Harrison, PhD, to its Scientific Advisory Board. Dr. Harrison is an internationally acknowledged specialist for design of human clinical outcome measurement in Alzheimer’s disease and other cognitive impairments. “Dr. Harrison brings…

Anavex CEO to Participate in Brean Capital 2013 Life Sciences Summit

New York, NY — November 21, 2013 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical stage biopharmaceutical company engaged in the development of novel drug candidates for the treatment of Alzheimer’s disease, CNS and oncology, today announced that its President and Chief Executive Officer Christopher U. Missling, PhD, will participate…